GHK-Cu Peptide Guide: Research Reference and Reported Amounts

Overview

GHK-Cu is a copper-binding tripeptide with an unusually broad research literature: collagen synthesis, wound-healing models, antioxidant activity, and gene-expression changes associated with tissue remodeling. This reference guide collects what published studies report about GHK-Cu, how concentration arithmetic works for a vial, and how to verify that material actually contains what its label claims. It does not describe how to administer GHK-Cu, and GHK-Cu is not approved for human use by any regulator. For concentration and dilution math, see our GHK-Cu calculator →

What GHK-Cu is and where the research comes from

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) complexed with copper(II). It was isolated from human plasma in the 1970s, and the subsequent literature splits into three broad areas: in-vitro work on fibroblast and collagen gene expression, animal-model work on wound healing, and a smaller body of topical human research in cosmetic and wound-care contexts. The in-vitro work is where most of the mechanistic claims originate.

The distinction matters when reading summaries. A finding that GHK-Cu upregulates collagen-related genes in cultured fibroblasts is not the same claim as a finding that it improves skin in humans. Where studies report positive results, they do so in specific models with specific endpoints.

What the research literature reports

The table below reproduces amounts as reported in published studies, for reference. Different studies used different preparations — subcutaneous, topical, and in-vitro — and the figures are not interchangeable across those routes.

Preparation	Amount reported in studies	Interval studied	Research context
Subcutaneous (research use)	1-2 mg	daily or 5x per week	Tissue-remodeling and collagen studies
Topical cosmetic formulations	0.05%-0.2% concentration	daily application	Skin-quality and wound-healing studies
In-vitro cell culture	micromolar range	continuous exposure	Fibroblast and gene-expression work

These are study parameters administered under protocol supervision. They are not a regimen to follow. Reproducing a published figure carries no implication that it is appropriate for any particular use.

Concentration arithmetic for a vial

A label states a mass. The concentration is created by the diluent volume you add, so two vials of the same nominal mass reconstituted differently give different concentrations, and therefore different volumes for the same amount of material. Before comparing anything against a published figure, express both sides in the same units — usually mg/mL or mcg/mL.

Worked example: 50 mg of material in 10 mL of diluent gives 5 mg/mL. An amount of 2 mg corresponds to 2 ÷ 5 = 0.4 mL. Our GHK-Cu calculator → shows the intermediate values so the arithmetic can be checked by hand.

Note that topical and injectable preparations are not interchangeable, and the percentages in cosmetic formulations do not convert into an injectable figure.

Verifying what is in a vial

A calculator assumes the label is accurate. Independent verification is a separate step:

• HPLC purity testing — establishes what proportion of the material is the target compound
• Mass spectrometry — confirms molecular identity; a copper-complexed tripeptide is not trivially distinguished from a related peptide by mass alone
• Copper content assay — GHK without its copper is a different material; a purity figure that does not address the copper complex omits the defining feature
• Batch-matched certificate of analysis — ties the result to the specific lot you hold; a COA for another lot proves nothing about yours

Our vendor pages record which suppliers publish batch-level COAs, and the forum collects community testing results — including failed tests — alongside supplier discussion. In independent testing, mislabelled or substituted material is common enough that an unverified label should be treated as a claim rather than a fact.

How GHK-Cu is positioned relative to other peptides

GHK-Cu appears in two distinct consumer contexts, and conflating them is the most common source of confusion:

• Cosmetic and dermatological research — topical formulations, where the human data largely lives
• Research-peptide supply — lyophilised powder sold for laboratory research, which is what "GHK-Cu peptide" usually refers to in supplier listings

Our vendor pages and comparison tools track supplier-reported data and independent testing results, not consumer experience claims. Where we summarise findings, we cite the study type so a reader can weigh an in-vitro result differently from a clinical one.

Handling and storage conventions

Unreconstituted (lyophilised) material is generally stable at ambient temperature for the duration of normal shipping and is typically stored frozen for longer-term stability. Once a diluent is added, the solution is usually refrigerated and used within a defined window, because the reconstituted state is less stable than the powder. Copper-complexed peptides are also sensitive to chelating agents and to some buffer conditions. These are handling conventions rather than arithmetic — verify them against the supplier's own documentation.

What the research shows, and what it does not

GHK-Cu has a longer and broader research history than most peptides sold as research material, particularly in topical wound-healing and cosmetic settings. That breadth is real. What it does not establish is an approved human regimen: there is no approved injectable GHK-Cu product, the injectable research literature is thin relative to the in-vitro work, and the endpoints in cosmetic studies are largely visual and short-term.

The honest summary is that the mechanistic and in-vitro literature is substantial, the topical human literature is modest, and the injectable human evidence is minimal. Anyone assessing GHK-Cu should weigh which of those three bodies of evidence they are actually relying on.

Related Peptides

Frequently Asked Questions

Related Guides